Pegcetacoplan 54 mg/mL, 15 mg/mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 54 mg/mL, 15 mg/mL
Reference Brands: Empaveli (USA/EU), Syfovre(USA/EU)
Category: Opthalmology
Pegcetacoplan is a targeted complement inhibitor that binds to complement protein C3, preventing its cleavage and downstream inflammatory effects. It is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy secondary to age-related macular degeneration (AMD). It helps reduce red blood cell destruction and slow retinal damage progression.
Product Description:
Pegcetacoplan is a pegylated peptide inhibitor that targets human complement components C3 and C3b, playing an important role in the treatment of diseases driven by excessive complement activation. By selectively binding to C3 and C3b, pegcetacoplan blocks the activation of the complement pathway, helping to reduce complement-mediated inflammation and cell destruction. This mechanism is particularly important in conditions where the immune system damages healthy cells and tissues.
Pegcetacoplan is primarily used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by the destruction of red blood cells. It is also approved in certain regions for the treatment of geographic atrophy associated with age-related macular degeneration. In addition, pegcetacoplan is being studied or used in conditions such as cold agglutinin disease and C3 glomerulopathy, where complement system dysregulation contributes to disease progression.
By targeting C3, a central component of the complement system and an essential part of the innate immune response, pegcetacoplan helps control abnormal immune activity and prevent tissue damage. This targeted approach provides a valuable therapeutic option for patients with complement-mediated disorders and related inflammatory diseases.
Pegcetacoplan — third party manufacturing & bulk supply
Pegcetacoplan 54 mg/mL, 15 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Pegcetacoplan listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Pegcetacoplan →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Pegcetacoplan is used for the treatment of certain complement-mediated disorders. It is primarily indicated for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition where red blood cells are destroyed prematurely by the immune system. It is also approved in some regions for the treatment of geographic atrophy associated with age-related macular degeneration. Pegcetacoplan works by inhibiting the complement component C3, which helps reduce red blood cell destruction and disease progression.
Pegcetacoplan is a targeted complement inhibitor composed of a synthetic cyclic peptide conjugated to polyethylene glycol (PEG). This structure allows the drug to bind specifically to complement protein C3 and C3b, helping block activation of the complement cascade that contributes to inflammation and cell damage.
Pegcetacoplan is marketed under the trade names Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria and Syfovre for the treatment of geographic atrophy in ophthalmology.
Pegcetacoplan was developed and is marketed by Apellis Pharmaceuticals, a biotechnology company focused on complement inhibition therapies.
The generic name of the medicine is pegcetacoplan.
The main brand names are Empaveli and Syfovre.
Pegcetacoplan is manufactured through global biologics manufacturing facilities that supply approved markets such as the United States, Europe, and other regulated regions, following international pharmaceutical quality and regulatory standards.
Related Products
Artificial Tears
Strength:
0.3% to 1%
Form: Eye Drops/ Eye Gel/ Eye ointment
Reference Brands: Refresh Tears (USA/LATAM), Hylo-Tear (EU), Refresh Liquigel (India)
View Details
Tetrahydrozoline Hydrochloride
Strength:
0.05%
Form: Eye Drops
Reference Brands: Visine (USA/EU / LATAM), Ocuvis (India)
View Details
Quick Response Guaranteed | Verified Suppliers
